#1 Clinical Trials Search in Europe

Paroxetine Hydrochloride

This article discusses clinical trials involving Paroxetine Hydrochloride, a medication used to treat various anxiety disorders and depression. The trials focus on comparing different formulations of Paroxetine, assessing its bioequivalence under different conditions, and evaluating its efficacy in treating social anxiety disorder. These studies aim to provide valuable insights into the drug’s absorption, effectiveness, and safety profile.

Table of Contents

What is Paroxetine Hydrochloride?

Paroxetine Hydrochloride is a medication used to treat various mental health conditions. It belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also known by its brand name Paxil[1]. This medication works by affecting certain chemicals in the brain that may become unbalanced in people with depression, anxiety, and other mental health disorders.

Conditions Treated by Paroxetine

Paroxetine is used to treat several mental health conditions, including:

  • Anxiety Disorders: This includes generalized anxiety disorder, social anxiety disorder (also known as social phobia), and panic disorder[1][2]
  • Major Depressive Disorder: A condition characterized by persistent feelings of sadness and loss of interest[2]
  • Obsessive-Compulsive Disorder (OCD): A disorder involving recurring, unwanted thoughts (obsessions) and repetitive behaviors (compulsions)[2]
  • Post-Traumatic Stress Disorder (PTSD): A condition that can develop after experiencing or witnessing a traumatic event[3]

How Paroxetine Works

Paroxetine works by increasing the levels of a neurotransmitter called serotonin in the brain. Serotonin is a chemical messenger that helps regulate mood, emotions, and other mental processes. By increasing serotonin levels, paroxetine can help improve symptoms of depression, anxiety, and other mental health conditions[1].

Dosage Forms and Administration

Paroxetine is available in various forms and strengths:

  • Film-coated tablets: 20 mg and 40 mg[4][5]
  • Oral tablets: 20 mg[2]

The medication is typically taken once daily, often in the evening after a meal. The dosage may vary depending on the condition being treated and the individual patient’s response. Always follow your doctor’s instructions regarding dosage and administration[3].

Bioequivalence Studies

Several studies have been conducted to compare the bioequivalence of generic paroxetine formulations with the brand-name version (Paxil). Bioequivalence means that the generic version is expected to have the same effect as the brand-name drug. These studies looked at how the body absorbs and processes the medication under different conditions:

  • Fasting conditions: Studies compared the absorption of paroxetine when taken without food[1][5]
  • Fed conditions: Other studies examined how food affects the absorption of paroxetine[4][2]

These studies help ensure that generic versions of paroxetine work similarly to the brand-name version.

Efficacy and Safety Studies

Clinical trials have been conducted to evaluate the effectiveness and safety of paroxetine for various conditions:

  • Social Anxiety Disorder (SAD): Studies have shown that paroxetine can be effective in reducing symptoms of social anxiety over a 12-week period[6]
  • Long-term use: A 52-week study examined the long-term effects of paroxetine in treating social anxiety disorder[7]
  • Post-Traumatic Stress Disorder (PTSD): A 52-week study evaluated the efficacy and safety of paroxetine in Japanese patients with PTSD[3]

Potential Side Effects

Like all medications, paroxetine can cause side effects. Some of the potential side effects observed in clinical studies include:

  • Changes in vital signs (e.g., blood pressure, heart rate)[1]
  • Non-serious adverse events (mild to moderate side effects)[1]
  • Serious adverse events (rare but potentially severe side effects)[1]

It’s important to discuss any side effects you experience with your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your specific situation.

Aspect Details
Study Types Bioequivalence studies, efficacy studies, long-term safety studies
Formulations Studied Paroxetine Hydrochloride tablets (various strengths), Paxil® (brand-name comparator)
Conditions Fasting and fed states
Primary Outcomes Cmax, AUC0-inf, AUC0-t, Tmax
Study Duration Single-dose studies (72-120 hours), long-term studies (up to 52 weeks)
Target Conditions Social Anxiety Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Generalized Anxiety Disorder
Safety Assessments Adverse events, vital signs, long-term tolerability
Efficacy Measures LSAS total score, CGI scores, HAM-D total score

FAQ

  • What is the main purpose of the bioequivalence studies for Paroxetine Hydrochloride? The main purpose of the bioequivalence studies is to compare the rate and extent of absorption of different formulations of Paroxetine Hydrochloride, such as generic versions and brand-name Paxil®, under various conditions (fasting and fed states).
  • What are the primary outcomes measured in these clinical trials? The primary outcomes typically include maximum observed concentration (Cmax) of Paroxetine in plasma, area under the concentration-time curve (AUC), and time to reach maximum concentration (Tmax). These measurements help determine if different formulations are bioequivalent.
  • How long do the bioequivalence studies usually last? The bioequivalence studies often involve collecting blood samples over a period of 72 to 120 hours after administering a single dose of the medication.
  • What conditions are being studied for Paroxetine Hydrochloride treatment? The clinical trials focus on various anxiety disorders, including Social Anxiety Disorder (SAD), Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, and Generalized Anxiety Disorder.
  • Are there any long-term studies conducted with Paroxetine Hydrochloride? Yes, there are long-term studies, such as a 52-week open-label study, designed to evaluate the efficacy and safety of Paroxetine Hydrochloride in treating Social Anxiety Disorder over an extended period.

Ongoing Clinical Trials on Paroxetine Hydrochloride

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Study on Temporarily Stopping Duloxetine, Sertraline, and Paroxetine in Patients with Hip or Knee Osteoarthritis Undergoing Surgery

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Stopping Antidepressants: Comparing Tapering Methods for Patients with Major Depressive Disorder Using Venlafaxine or Paroxetine Hydrochloride

    Not recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Bioequivalence: A comparison of the biological equivalence of two products with the same active ingredient, typically measured by the rate and extent of drug absorption.
  • Cmax: The maximum observed concentration of a drug in the blood plasma after administration.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, calculated from a graph of drug concentration in the blood plasma versus time.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood plasma after administration.
  • Fasting Conditions: A state where the subject has not eaten for a specified period before and after taking the medication.
  • Fed Conditions: A state where the subject has eaten a meal before taking the medication, used to study how food affects drug absorption.
  • Crossover Study: A type of clinical trial where participants receive different treatments in a specific order, allowing each person to serve as their own control.
  • LSAS (Liebowitz Social Anxiety Scale): A questionnaire used to assess the severity of social anxiety disorder symptoms.
  • CGI (Clinical Global Impression): A scale used by healthcare professionals to evaluate the overall severity of a patient's condition and its improvement over time.
  • HAM-D (Hamilton Depression Rating Scale): A multiple-item questionnaire used to provide an indication of depression and as a guide to evaluate recovery.

References

  1. https://clinicaltrials.gov/study/NCT04311463
  2. https://clinicaltrials.gov/study/NCT03504475
  3. https://clinicaltrials.gov/study/NCT00839397
  4. https://clinicaltrials.gov/study/NCT00841659
  5. https://clinicaltrials.gov/study/NCT00841698
  6. https://clinicaltrials.gov/study/NCT00318669
  7. https://clinicaltrials.gov/study/NCT00264654